BR3006 Clinical Trials (2026): 3 Studies for Type 2 Diabetes & Diabetes Mellitus
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 BR3006 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Type 2 Diabetes & Diabetes Mellitus) and 130 total planned enrollment. Most recent activity: NCT06890299 (Jan 2025).
BR3006 clinical trials at a glance: phase × recruitment status
| Phase | completed | Total |
|---|---|---|
| P1 | 3 | 3 |
BR3006 clinical trials by indication
Type 2 Diabetes (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06890299 | — | P1 | completed | A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions |
| NCT06890286 | — | P1 | completed | A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions |
Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05951946 | — | P1 | completed | A Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers |
All BR3006 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06890299 | A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions | P1 | completed | 40 | Boryung Pharmaceutical Co., Ltd | Dec 2024 | |
| NCT06890286 | A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions | P1 | completed | 53 | Boryung Pharmaceutical Co., Ltd | Dec 2024 | |
| NCT05951946 | A Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers | P1 | completed | 37 | Boryung Pharmaceutical Co., Ltd | Jul 2023 |
BR3006 clinical trials: frequently asked questions
- How many BR3006 clinical trials are there?
- 3 BR3006 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are marked completed.
- Are BR3006 clinical trials recruiting in 2026?
- No active BR3006 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is BR3006 being studied for?
- BR3006 is being studied for Type 2 Diabetes, Diabetes Mellitus. The trials are grouped by indication on this page.
- What phase is BR3006 in?
- BR3006 clinical trials span 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors BR3006 clinical trials?
- The lead sponsor across the most BR3006 trials is Boryung Pharmaceutical Co., Ltd. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming BR3006as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: